Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

CONCLUSION: A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.PMID:38042707 | DOI:10.1016/j.arbres.2023.11.011

Source: Archivos de Bronconeumologia - December 2, 2023 Category: Respiratory Medicine Authors: Marcela Valverde-Monge Patricia S ánchez-Carrasco Diana Betancor Blanca Barroso Jos é Manuel Rodrigo-Muñoz Ignacio Mahillo-Fern ández Ebymar Arismendi Irina Bobolea Blanca C árdaba Mar ía Jesús Cruz Victoria Del Pozo Javier Dom ínguez-Ortega Franc Source Type: research